Last updated on December 2018

Patients are needed to participate in a clinical research study to evaluate Human Papillomavirus Infection, Condyloma acuminatum, Malignant neoplasm of vulva, Vaginal Cancer, Cervical Cancer

Brief description of study

This study will assess the safety and immunogenicity of GARDASIL9 (V503) in 27- to 45-year-old women, and will complete the evaluation of GARDASIL9 in the extended age range of female participants for whom GARDASIL was proven to be effective. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 titers at 4 weeks postdose 3 are non-inferior in adult women as compared with titers in young adult women.

Clinical Study Identifier: NCT03158220

Contact Investigators or Research Sites near you

Start Over

CAP Centelles ( Site 0027)

Centelles, Spain

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.